In the last trading session, 2.03 million shares of the Lyell Immunopharma Inc (NASDAQ:LYEL) were traded, and its beta was -0.36. Most recently the company’s share price was $0.55, and it changed around -$0.02 or -3.50% from the last close, which brings the market valuation of the company to $161.71M. LYEL currently trades at a discount to its 52-week high of $3.26, offering almost -492.73% off that amount. We note from Lyell Immunopharma Inc’s average daily trading volume that its 10-day average is 1.11 million shares, with the 3-month average coming to 1.18 million.
Lyell Immunopharma Inc stock received a consensus recommendation rating of Hold, based on a mean score of 3.33. If we narrow it down even further, the data shows that 0 out of 4 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 3 recommended LYEL as a Hold, whereas 0 deemed it a Buy, and 1 rated it as Underweight. Lyell Immunopharma Inc is expected to report earnings per share of -0.13 for the current quarter.
Lyell Immunopharma Inc (NASDAQ:LYEL) trade information
Instantly LYEL has showed a red trend with a performance of -3.50% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 0.6355 on recent trading dayincreased the stock’s daily price by 13.45%. The company’s shares are currently down -13.52% year-to-date, but still down -5.30% over the last five days. On the other hand, Lyell Immunopharma Inc (NASDAQ:LYEL) is -15.07% down in the 30-day period. We can see from the shorts that 12.4 million shares have been sold at a short interest cover period of 10.75 day(s).
The consensus price target as assigned by Wall Street analysts is $1, which translates to bulls needing to increase their stock price by 45.0% from its current value. Analyst projections state that LYEL is forecast to be at a low of $1 and a high of $1.
Lyell Immunopharma Inc (LYEL) estimates and forecasts
The year-over-year growth rate is expected to be -59.23%, down from the previous year.
Analysts predict that the company’s current quarter sales will drop, forecast at -100.00%. Forecasts for the next quarter put sales growth at 0.00%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -15.28%. Lyell Immunopharma Inc earnings are expected to increase by 21.51% in 2025, but the outlook is positive 17.62% per year for the next five years.
LYEL Dividends
Lyell Immunopharma Inc’s next quarterly earnings report is expected to be released in March.
Lyell Immunopharma Inc (NASDAQ:LYEL)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 13.44% of Lyell Immunopharma Inc shares, and 58.62% of them are in the hands of institutional investors. The stock currently has a share float of 67.72%. Lyell Immunopharma Inc stock is held by 155.0 institutions, with MWG MANAGEMENT LTD. being the largest institutional investor. By 2024-06-30, it held 7.9301% of the shares, which is about 20.16 million shares worth $29.24 million.
ORLAND PROPERTIES LTD, with 5.9366% or 15.09 million shares worth $21.89 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
